These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 31861854)

  • 1. Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
    Mhibik M; Wiestner A; Sun C
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
    Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
    Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
    Ann Hematol; 2024 Jul; 103(7):2231-2244. PubMed ID: 37843620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
    Jain N; O'Brien S
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):851-60, x. PubMed ID: 23915749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
    Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
    Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
    Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of BTK inhibitors on the tumor microenvironment in CLL.
    McCay J; Gribben JG
    Leuk Lymphoma; 2022 Sep; 63(9):2023-2032. PubMed ID: 35465824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
    Palma M; Mulder TA; Österborg A
    Front Immunol; 2021; 12():686768. PubMed ID: 34276674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BTK in CLL: Beyond Ibrutinib.
    Bond DA; Woyach JA
    Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Tang CPS; McMullen J; Tam C
    Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on.
    Molica S; Matutes E; Tam C; Polliack A
    Hematol Oncol; 2020 Apr; 38(2):129-136. PubMed ID: 31732977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
    Bond DA; Maddocks KJ
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV
    Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib: a paradigm shift in management of CLL.
    Badar T; Burger JA; Wierda WG; O'Brien S
    Expert Rev Hematol; 2014 Dec; 7(6):705-17. PubMed ID: 25387837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.